Dubravka Smiljkovic1, Renata Kiss2, Christian Lupinek2, Gregor Hoermann3, Georg Greiner4, Nadine Witzeneder5, Gerhard Krajnik6, Franz Trautinger7, Susanne Vrtala2, Irene Mittermann2, Michael Kundi8, Bernd Jilma9, Rudolf Valenta10, Wolfgang R Sperr11, Peter Valent12. 1. Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria. 2. Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Immunology and Infectiology, Medical University of Vienna, Vienna, Austria. 3. Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital Innsbruck, Innsbruck, Austria. 4. Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. 5. Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria. 6. Department of Internal Medicine I, University Hospital St. Poelten, St. Poelten, Austria. 7. Department of Dermatology, University Hospital St. Poelten, St. Poelten, Austria. 8. Institute of Environmental Health of the Medical University of Vienna, Vienna, Austria. 9. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. 10. Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Immunology and Infectiology, Medical University of Vienna, Vienna, Austria; NRC Institute of Immunology FMBA of Russia, Moscow, Russia; Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia; Karl Landsteiner University of Health Sciences, Krems, Austria. 11. Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: wolfgang.r.sperr@meduniwien.ac.at. 12. Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: peter.valent@meduniwien.ac.at.
Abstract
BACKGROUND: Because of a high risk to develop fatal anaphylaxis, early detection of immunoglobulin E (IgE)-dependent allergy is of particular importance in patients with mastocytosis. OBJECTIVE: We examined whether microarray-based screening for allergen-reactive IgE (allergen-chip) is a sensitive and robust approach to detect specific IgE in patients with mastocytosis. METHODS: Sera for 42 patients were analyzed, including 4 with cutaneous mastocytosis, 2 with mastocytosis in the skin, and 36 with systemic mastocytosis. In addition, sera from an age- and sex-matched control cohort (n = 42) were analyzed. RESULTS: In 15 of 42 patients with mastocytosis (35.7%), specific IgE was detected by allergen-chip profiling. Ves v 5 and Bet v 1 were the most frequently detected allergens (Ves v 5: 16.7% of patients; Bet v 1: 11.9% of patients). Allergen reactivity was confirmed by demonstrating upregulation of CD203c on blood basophils upon exposure to the respective allergen(s) in these patients. Specific IgE was identified by chip studies in 11 of 26 patients with mastocytosis with mediator-related symptoms (42.3%) and in 4 of 14 patients with mastocytosis without symptoms (28.6%). In the cohort with known allergy, 9 of 9 patients (100%) had a positive allergen-chip result. In patients with mastocytosis without a known allergy (n = 31), the chip identified 6 positive cases (19.5%). The prevalence of chip-positive patients was slightly lower in the mastocytosis group (35.7%) compared with age- and sex-matched controls (40.5%). CONCLUSIONS: Although specific IgE may not be detectable in all sensitized patients with mastocytosis, allergy chip-profiling is a reliable screening approach for the identification of patients with mastocytosis suffering from IgE-dependent allergies.
BACKGROUND: Because of a high risk to develop fatal anaphylaxis, early detection of immunoglobulin E (IgE)-dependent allergy is of particular importance in patients with mastocytosis. OBJECTIVE: We examined whether microarray-based screening for allergen-reactive IgE (allergen-chip) is a sensitive and robust approach to detect specific IgE in patients with mastocytosis. METHODS: Sera for 42 patients were analyzed, including 4 with cutaneous mastocytosis, 2 with mastocytosis in the skin, and 36 with systemic mastocytosis. In addition, sera from an age- and sex-matched control cohort (n = 42) were analyzed. RESULTS: In 15 of 42 patients with mastocytosis (35.7%), specific IgE was detected by allergen-chip profiling. Ves v 5 and Betv 1 were the most frequently detected allergens (Ves v 5: 16.7% of patients; Betv 1: 11.9% of patients). Allergen reactivity was confirmed by demonstrating upregulation of CD203c on blood basophils upon exposure to the respective allergen(s) in these patients. Specific IgE was identified by chip studies in 11 of 26 patients with mastocytosis with mediator-related symptoms (42.3%) and in 4 of 14 patients with mastocytosis without symptoms (28.6%). In the cohort with known allergy, 9 of 9 patients (100%) had a positive allergen-chip result. In patients with mastocytosis without a known allergy (n = 31), the chip identified 6 positive cases (19.5%). The prevalence of chip-positive patients was slightly lower in the mastocytosis group (35.7%) compared with age- and sex-matched controls (40.5%). CONCLUSIONS: Although specific IgE may not be detectable in all sensitized patients with mastocytosis, allergy chip-profiling is a reliable screening approach for the identification of patients with mastocytosis suffering from IgE-dependent allergies.
Authors: Anna Asarnoj; Carl Hamsten; Christian Lupinek; Erik Melén; Niklas Andersson; Josep M Anto; Jean Bousquet; Rudolf Valenta; Marianne van Hage; Magnus Wickman Journal: J Allergy Clin Immunol Date: 2017-02-09 Impact factor: 10.793
Authors: M Sørensen; C Klingenberg; M Wickman; J U E Sollid; A-S Furberg; C Bachert; J Bousquet Journal: Allergy Date: 2017-05-04 Impact factor: 13.146
Authors: Josep M Anto; Jean Bousquet; Mubeccel Akdis; Charles Auffray; Thomas Keil; Isabelle Momas; Dirkje S Postma; Rudolf Valenta; Magnus Wickman; Anne Cambon-Thomsen; Tari Haahtela; Bart N Lambrecht; Karin C Lodrup Carlsen; Gerard H Koppelman; Jordi Sunyer; Torsten Zuberbier; Isabelle Annesi-Maesano; Albert Arno; Carsten Bindslev-Jensen; Giuseppe De Carlo; Francesco Forastiere; Joachim Heinrich; Marek L Kowalski; Dieter Maier; Erik Melén; Henriette A Smit; Marie Standl; John Wright; Anna Asarnoj; Marta Benet; Natalia Ballardini; Judith Garcia-Aymerich; Ulrike Gehring; Stefano Guerra; Cynthia Hohmann; Inger Kull; Christian Lupinek; Mariona Pinart; Ingebjorg Skrindo; Marit Westman; Delphine Smagghe; Cezmi Akdis; Niklas Andersson; Claus Bachert; Stephane Ballereau; Ferran Ballester; Xavier Basagana; Anna Bedbrook; Anna Bergstrom; Andrea von Berg; Bert Brunekreef; Emilie Burte; Kai-Hakon Carlsen; Leda Chatzi; Jonathan M Coquet; Mirela Curin; Pascal Demoly; Esben Eller; Maria Pia Fantini; Leena von Hertzen; Vergard Hovland; Benedicte Jacquemin; Jocelyne Just; Theresa Keller; Renata Kiss; Manolis Kogevinas; Sibylle Koletzko; Susanne Lau; Irina Lehmann; Nicolas Lemonnier; Mika Mäkelä; Jordi Mestres; Peter Mowinckel; Rachel Nadif; Martijn C Nawijn; Johan Pellet; Isabelle Pin; Daniela Porta; Fanny Rancière; Emmanuelle Rial-Sebbag; Yvan Saeys; Martijn J Schuijs; Valerie Siroux; Christina G Tischer; Mathies Torrent; Raphaelle Varraso; Kalus Wenzel; Cheng-Jian Xu Journal: J Allergy Clin Immunol Date: 2017-02 Impact factor: 10.793
Authors: Anna Asarnoj; Carl Hamsten; Konrad Wadén; Christian Lupinek; Niklas Andersson; Inger Kull; Mirela Curin; Josep Anto; Jean Bousquet; Rudolf Valenta; Magnus Wickman; Marianne van Hage Journal: J Allergy Clin Immunol Date: 2015-12-10 Impact factor: 10.793
Authors: Michael Kneidinger; Uwe Schmidt; Uwe Rix; Karoline V Gleixner; Anja Vales; Christian Baumgartner; Christian Lupinek; Margit Weghofer; Keiryn L Bennett; Harald Herrmann; Alexandra Schebesta; Wayne R Thomas; Susanne Vrtala; Rudolf Valenta; Francis Y Lee; Wilfried Ellmeier; Giulio Superti-Furga; Peter Valent Journal: Blood Date: 2008-01-07 Impact factor: 22.113
Authors: Jason Gotlib; Tracy I George; Melody C Carter; K Frank Austen; Bruce Bochner; Daniel F Dwyer; Jonathan J Lyons; Matthew J Hamilton; Joseph Butterfield; Patrizia Bonadonna; Catherine Weiler; Stephen J Galli; Lawrence B Schwartz; Hanneke Oude Elberink; Anne Maitland; Theoharis Theoharides; Celalettin Ustun; Hans-Peter Horny; Alberto Orfao; Michael Deininger; Deepti Radia; Mohamad Jawhar; Hanneke Kluin-Nelemans; Dean D Metcalfe; Michel Arock; Wolfgang R Sperr; Peter Valent; Mariana Castells; Cem Akin Journal: J Allergy Clin Immunol Date: 2021-03-11 Impact factor: 14.290
Authors: Peter Valent; Cem Akin; Boguslaw Nedoszytko; Patrizia Bonadonna; Karin Hartmann; Marek Niedoszytko; Knut Brockow; Frank Siebenhaar; Massimo Triggiani; Michel Arock; Jan Romantowski; Aleksandra Górska; Lawrence B Schwartz; Dean D Metcalfe Journal: Int J Mol Sci Date: 2020-11-27 Impact factor: 5.923
Authors: Peter Valent; Karin Hartmann; Patrizia Bonadonna; Marek Niedoszytko; Massimo Triggiani; Michel Arock; Knut Brockow Journal: Int Arch Allergy Immunol Date: 2022-05-23 Impact factor: 3.767